(Total Views: 768)
Posted On: 08/22/2020 2:04:49 AM
Post# of 155734
The science isn't in on VIP applications.
I looked around and found Dr.Javitt on YO. Interestingly he described mechanistic effects which were diametrically opposed to the mechanistic description of VIP given in the link to Dr.Been. Notably the chronotropic and inotropic cardiovascular effects, requiring the use of pressors.
It looks like the inhaled version for the mild to moderates is going to be some form of nebulizer that will go on for some period of time... not just a squirt and go solution. And it will probably be repeated up to 4 times a day. The clinical question will be... can you get enough into the lungs to get the effects that you want.. probably. Can you clear the viremia without having your patients becoming hypotensive? A lot can happen when you become hypotensive and most of it isn't good. There is a lot of individual variation. Some will be sensitive to it, others won't. My guess is that the first death with stop the trial on mild to moderates. The data will show the truth.
I looked around and found Dr.Javitt on YO. Interestingly he described mechanistic effects which were diametrically opposed to the mechanistic description of VIP given in the link to Dr.Been. Notably the chronotropic and inotropic cardiovascular effects, requiring the use of pressors.
It looks like the inhaled version for the mild to moderates is going to be some form of nebulizer that will go on for some period of time... not just a squirt and go solution. And it will probably be repeated up to 4 times a day. The clinical question will be... can you get enough into the lungs to get the effects that you want.. probably. Can you clear the viremia without having your patients becoming hypotensive? A lot can happen when you become hypotensive and most of it isn't good. There is a lot of individual variation. Some will be sensitive to it, others won't. My guess is that the first death with stop the trial on mild to moderates. The data will show the truth.
(1)
(0)
